235 related articles for article (PubMed ID: 10566038)
1. CDP 571. Anti-TNF monoclonal antibody, BAY 103356.
Drugs R D; 1999 Mar; 1(3):253-5. PubMed ID: 10566038
[No Abstract] [Full Text] [Related]
2. Interleukin-10. Cytokine synthesis inhibitory factor, SCH 52000, rIL-10, rhIL-10.
Drugs R D; 1999 Mar; 1(3):262-4. PubMed ID: 10566041
[No Abstract] [Full Text] [Related]
3. Etanercept. Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR 001, Enbrel.
Drugs R D; 1999 Mar; 1(3):258-61. PubMed ID: 10566040
[No Abstract] [Full Text] [Related]
4. Ridogrel. R 68070.
Drugs R D; 1999 Mar; 1(3):270-2. PubMed ID: 10566044
[No Abstract] [Full Text] [Related]
5. E 3040.
Drugs R D; 1999 Mar; 1(3):256-7. PubMed ID: 10566039
[No Abstract] [Full Text] [Related]
6. Acemannan. CARN 1000, CARN 750, polymannoacetate, Aliminase, Alovex, Carrisyn.
Drugs R D; 1999 Mar; 1(3):251-2. PubMed ID: 10566037
[No Abstract] [Full Text] [Related]
7. Infliximab in ulcerative colitis.
Aberra FN; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
[TBL] [Abstract][Full Text] [Related]
8. Is infliximab effective for induction of remission in patients with ulcerative colitis?
Lichtenstein GR
Inflamm Bowel Dis; 2001 May; 7(2):89-93. PubMed ID: 11383596
[No Abstract] [Full Text] [Related]
9. ISIS 2302. Oligo-TCS.
Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
[No Abstract] [Full Text] [Related]
10. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
Peyrin-Biroulet L
Am J Gastroenterol; 2013 May; 108(5):859-60. PubMed ID: 23644972
[No Abstract] [Full Text] [Related]
11. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
Sandborn WJ
Rev Gastroenterol Disord; 2005; 5(1):10-8. PubMed ID: 15741928
[TBL] [Abstract][Full Text] [Related]
12. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?
Reenaers C; Belaiche J; Louis E
Inflamm Bowel Dis; 2010 Aug; 16(8):1271-2. PubMed ID: 20027649
[No Abstract] [Full Text] [Related]
13. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
Shanahan F
Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074
[No Abstract] [Full Text] [Related]
14. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
15. [Anti-TNF agents in inflammatory bowel disease: indications and management].
Cocq P; Yazdanpannah Y; Mesnard B; Colombel JF
Gastroenterol Clin Biol; 2004 May; 28(5 Suppl):D61-9. PubMed ID: 15213665
[No Abstract] [Full Text] [Related]
16. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
17. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
Peng JC; Shen J; Ran ZH
J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
[TBL] [Abstract][Full Text] [Related]
18. [Mexican consensus on the use of agents anti-TNF-alpha in the treatment of inflammatory bowel disease.].
Yamamoto-Furusho JK; Bosques-Padilla F;
Rev Gastroenterol Mex; 2009; 74(3):263-78. PubMed ID: 19858021
[TBL] [Abstract][Full Text] [Related]
19. The role of biologics in the treatment of patients with inflammatory bowel disease.
Selinger CP; Carbery I; Al-Asiry J
Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
[TBL] [Abstract][Full Text] [Related]
20. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
